HDIM
BIVV

Hanson & Doremus Investment Management’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Hanson & Doremus Investment Management’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-262
Closed -$14K – 518
2017
Q4 		$14K Hold
262
– – ﹤0.01% 419
2017
Q3 		$15K Hold
262
– – 0.01% 399
2017
Q2 		$16K Hold
262
– – 0.01% 392
2017
Q1 		$14K Buy
+262
New +$12.9K 0.01% 393

Other funds holding BIVV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Hanson & Doremus Investment Management's BIVV Position: Q1 2018 in Review

Hanson & Doremus Investment Management sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 262 shares — an estimated $14K sold.

Hanson & Doremus Investment Management first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $16K in Q2 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

  • Hanson & Doremus Investment Management reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Hanson & Doremus Investment Management sold 262 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $14K.
  • Hanson & Doremus Investment Management first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
  • Hanson & Doremus Investment Management's Bioverativ Inc. Common Stock position peaked at $16K in Q2 2017.
  • 2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Hanson & Doremus Investment Management's 13F filing for Q1 2018, filed 10 May 2018.